Enclomiphene Citrate vs Jatenzo: What To Do When One Fails

How These Two Drugs Actually Work

Enclomiphene citrate and Jatenzo sit at opposite ends of the male testosterone treatment spectrum. Enclomiphene blocks estrogen receptors in the hypothalamus, signaling the pituitary to secrete more LH and FSH, which then drives the testes to produce more testosterone. Jatenzo delivers pre-formed testosterone undecanoate through a lymphatic absorption pathway, bypassing first-pass hepatic metabolism entirely.

Enclomiphene: Axis-Dependent Testosterone Restoration

Enclomiphene is the trans-isomer of clomiphene citrate. By selectively blocking hypothalamic estrogen receptors, it removes negative feedback and triggers a surge in gonadotropin output. Because the testes must still function to respond, enclomiphene only works in secondary (hypogonadotropic) hypogonadism, not in primary testicular failure.

A 2016 study by Kim et al. (BJU Int, N=92) demonstrated that enclomiphene 12.5 mg daily raised mean serum testosterone from 232 ng/dL to 463 ng/dL over 16 weeks while simultaneously preserving sperm concentration above 15 million/mL in the majority of participants. [1] That dual hormonal and fertility response is the core clinical appeal.

Jatenzo: Direct Testosterone Replacement

Jatenzo (testosterone undecanoate 158 mg, 198 mg, 237 mg, 316 mg, or 396 mg capsules) is absorbed via intestinal lymphatics after a fat-containing meal and converted to testosterone in the bloodstream. Because it does not rely on the pituitary-gonadal axis, it works whether failure is primary or secondary.

Swerdloff et al. (J Clin Endocrinol Metab 2020, N=166) reported that 87% of men achieved an average total testosterone in the normal range (300 to 1,000 ng/dL) over a 52-week titration study. [2] Mean testosterone was 498 ng/dL at steady state. Dose titration occurred at weeks 4 and 8 based on mid-dose pharmacokinetic sampling.

FDA Approval Status and Off-Label Considerations

Jatenzo received FDA approval in March 2019 specifically for adult males with primary or secondary hypogonadism. [3] Enclomiphene citrate has not received FDA approval for hypogonadism as of this writing. The FDA rejected a New Drug Application from Repros Therapeutics in 2014, citing insufficient long-term cardiovascular and safety data. [4]

What "Off-Label" Means for Prescribers

Prescribers may still legally prescribe enclomiphene off-label, and many men's health clinics do. The American Urological Association's 2018 guidelines on male infertility acknowledge gonadotropin-stimulating agents as a treatment option for hypogonadotropic hypogonadism in men who want fertility preservation. [5] Off-label use transfers more risk-management responsibility to the ordering clinician, and that matters for malpractice exposure and insurance coverage.

Compounded vs. Brand Versions

Enclomiphene is available as a compounded preparation from 503B outsourcing facilities. FDA guidance has historically restricted large-scale compounding of FDA-approved drugs, but enclomiphene's non-approved status creates a gray zone. [6] Jatenzo is a branded product; no AB-rated generic exists.

Efficacy: Head-to-Head Data and What It Shows

No randomized controlled trial has directly compared enclomiphene citrate to Jatenzo in the same population. The comparison therefore relies on cross-trial data, which carries inherent limitations in baseline testosterone levels, inclusion criteria, and assay methods.

Testosterone Levels Achieved

In the Kim et al. 2016 trial, enclomiphene 25 mg raised mean total testosterone to approximately 500 ng/dL at 16 weeks in men with secondary hypogonadism (baseline T 232 ng/dL). [1] In the Swerdloff 2020 Jatenzo trial, mean total testosterone at steady state was 498 ng/dL across all dose groups combined. [2]

On raw testosterone numbers, they appear equivalent. The difference lies in which patients those numbers were achieved in: Jatenzo works regardless of axis function, enclomiphene requires intact testicular reserve.

Symptom Response

Testosterone-dependent symptom scores (International Index of Erectile Function, ADAM questionnaire) improved in both treatment arms across their respective trials. A 2014 Phase III trial of enclomiphene (N=303) reported statistically significant improvement in morning erections and libido scores versus placebo (P<0.001). [7] Jatenzo's key trial similarly showed improvement in hypogonadal symptom scores, though direct IIEF reporting was a secondary endpoint only. [2]

LH and FSH Suppression

This is the most clinically important efficacy difference. Jatenzo suppresses LH and FSH to near-undetectable levels in most men, which shuts down intratesticular testosterone production and sperm output. Enclomiphene raises LH and FSH, which does the opposite. A man who switches from enclomiphene to Jatenzo should expect his LH to drop below 1.0 mIU/mL within 4 to 6 weeks and his sperm count to fall substantially within 3 to 6 months. [8]

Side-Effect Profiles: Where Each Drug Creates Problems

Enclomiphene Side Effects

The most common adverse effects are visual disturbances (blurred vision, light sensitivity), mood changes, and elevated estradiol. Because enclomiphene raises LH and FSH, it also raises estrogen via aromatization of the higher circulating testosterone. Gynecomastia affects an estimated 3 to 5% of SERM-treated men in clinical series, though rates vary by dose and individual aromatase activity. [9]

Enclomiphene does not suppress erythropoiesis. Hematocrit elevation is not a clinically recognized concern with this drug. Blood pressure effects are minimal.

Jatenzo Side Effects

Jatenzo carries an FDA black box warning for blood pressure elevation. In the Swerdloff 2020 trial, 21% of participants required antihypertensive initiation or dose escalation during the 52-week study period. [2] That figure is not a minor footnote. Men with pre-existing hypertension, cardiovascular disease, or untreated sleep apnea face real added risk. [3]

Polycythemia is the other primary concern. Testosterone directly stimulates erythropoiesis; hematocrit above 54% occurred in approximately 5% of Jatenzo-treated men in the key trial. [2] Routine hematocrit monitoring at 3 and 6 months is standard of care per Endocrine Society guidelines. [10]

Defining Failure: Three Scenarios

"Failure" is not one thing. Before switching, a clinician should classify which of three failure modes applies.

Scenario 1: Subtherapeutic Testosterone Response

A man on enclomiphene 25 mg daily for 12 weeks still has total testosterone below 350 ng/dL and ongoing hypogonadal symptoms. Lab work shows LH and FSH rose appropriately (confirming SERM action), but testicular output is blunted. This pattern indicates primary testicular insufficiency that enclomiphene cannot override. Switching to Jatenzo is the logical next step because exogenous testosterone bypasses the unresponsive testes entirely.

Conversely, a man on Jatenzo 316 mg twice daily who cannot achieve total testosterone above 300 ng/dL mid-dose is a rare titration failure. Dose escalation to 396 mg twice daily should be tried first. If the maximum dose still yields inadequate levels, alternative delivery routes (injectable testosterone cypionate, transdermal T) typically outperform a SERM trial in this context, because the axis is already suppressed.

Scenario 2: Intolerable Side Effects

A man on enclomiphene who develops grade-2 gynecomastia or persistent visual disturbances needs to stop the SERM. Adding an aromatase inhibitor to control estrogen is sometimes tried before discontinuation, but combined SERM plus AI use lacks strong trial data in this setting. [9] Switching to Jatenzo removes the estrogen-stimulating mechanism but introduces cardiovascular and erythrocytosis risk.

A man on Jatenzo whose blood pressure climbs despite antihypertensive therapy should stop or switch. Enclomiphene is a reasonable alternative if he has secondary hypogonadism and fertility is a concern. Injectable testosterone cypionate, which does not carry Jatenzo's lymphatic absorption-related blood pressure signal, may also be preferable for men with cardiovascular risk factors. [10]

Scenario 3: Changed Fertility Goals

A man who started Jatenzo and now wants to conceive should stop Jatenzo and begin enclomiphene citrate (or injectable hCG/FSH if time is critical). Spermatogenesis recovery after exogenous testosterone cessation takes 3 to 12 months in most men, though some men with prolonged suppression may need gonadotropin support. [8] A 2013 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=1,549 across 30 studies) found that 67% of men recovered sperm concentrations to 20 million/mL within 6 months of stopping testosterone. [11] Starting enclomiphene during the recovery phase may accelerate return of gonadotropins and testicular function. [1]

Switching Protocols: Step-by-Step Clinical Guidance

The following framework reflects current prescribing practice at men's health clinics and is consistent with Endocrine Society guideline principles for testosterone therapy management. [10]

Switching From Enclomiphene to Jatenzo

1. Confirm the failure mode (inadequate T response vs. Side effects vs. Fertility status change).
2. Obtain baseline labs: total testosterone (morning), LH, FSH, estradiol, hematocrit, PSA, blood pressure.
3. Stop enclomiphene. No taper is required. LH and FSH will fall within 2 to 4 weeks as exogenous testosterone suppresses the axis.
4. Start Jatenzo at 237 mg twice daily with a fat-containing meal (at least 10 grams of fat per FDA labeling). [3]
5. Check total testosterone at week 4 using a mid-dose blood draw (approximately 6 hours post-dose for peak estimate, or per clinic protocol).
6. Titrate: if total testosterone is below 400 ng/dL, increase to 316 mg twice daily. If above 700 ng/dL at steady state, decrease dose. Maximum approved dose is 396 mg twice daily.
7. Recheck hematocrit and blood pressure at weeks 4, 8, and 26.
8. Counsel the patient that fertility will decline. If any chance of future conception exists, document the conversation and consider sperm banking before starting.

Switching From Jatenzo to Enclomiphene

1. Confirm secondary (hypogonadotropic) hypogonadism is the underlying diagnosis. Enclomiphene will not work in primary hypogonadism (elevated LH and FSH at baseline before Jatenzo started).
2. Stop Jatenzo. Testosterone levels will fall within 3 to 5 days given testosterone undecanoate's short half-life in oral form.
3. Wait 4 to 6 weeks for LH and FSH to recover before starting enclomiphene, to establish a true baseline gonadotropin response.
4. Start enclomiphene at 12.5 mg daily. Check total testosterone, LH, FSH, and estradiol at week 6.
5. If total testosterone remains below 350 ng/dL despite LH rising above 5 mIU/mL, primary testicular insufficiency is likely and enclomiphene should be discontinued. Return to exogenous testosterone.
6. If testosterone reaches 400 to 700 ng/dL with controlled estradiol, continue and recheck at 3-month intervals.

Cardiovascular and Metabolic Monitoring

Both drugs affect cardiovascular parameters, but through different mechanisms and with different risk magnitudes.

Blood Pressure Monitoring With Jatenzo

The FDA mandates blood pressure measurement before starting Jatenzo and at regular intervals during treatment. [3] In the key trial, the mean systolic blood pressure increase was 3 to 5 mmHg, which sounds modest, but 21% of men required antihypertensive treatment initiation, per Swerdloff et al. [2] Men with baseline systolic BP above 130 mmHg should have a structured antihypertensive plan in place before starting. The American Heart Association's 2017 hypertension guidelines classify systolic 130 to 139 mmHg as Stage 1 hypertension, and adding Jatenzo to that baseline warrants close follow-up. [12]

Lipid and Hematological Effects

Testosterone therapy broadly lowers HDL cholesterol by 5 to 10%. Jatenzo-treated men showed a mean HDL decrease of 7.4 mg/dL in the 52-week key trial. [2] Enclomiphene, by raising endogenous testosterone modestly, may have a smaller HDL effect, though dedicated lipid endpoint trials are lacking. Annual fasting lipid panels are standard for both. Erythrocytosis monitoring (hematocrit above 54%) is specific to Jatenzo and other exogenous testosterone formulations, not to enclomiphene. [10]

Patient Profiles: Who Should Start Which Drug

Ideal Enclomiphene Candidate

A man aged 25 to 45 with secondary hypogonadism (low total T, low or low-normal LH, identifiable cause such as obesity or prior opioid use), who wants to preserve fertility or is actively trying to conceive, and whose estradiol is not already elevated, is the best candidate. Men with obesity-related functional hypogonadism, where weight loss alone might eventually restore axis function, may also benefit from a time-limited enclomiphene trial before committing to lifelong testosterone replacement. [9]

Ideal Jatenzo Candidate

A man who wants FDA-approved oral testosterone therapy, who has either confirmed primary hypogonadism or secondary hypogonadism with no immediate fertility plans, who has well-controlled blood pressure at baseline, and who prefers oral dosing over injections or daily gels. The oral-twice-daily schedule with meals is less flexible than injectable testosterone cypionate (one injection every 1 to 2 weeks), but many men strongly prefer avoiding needles. [2]

A man with hematocrit above 50% at baseline, uncontrolled hypertension, or a recent cardiovascular event should not start Jatenzo until those conditions are addressed. [3]

Cost, Insurance, and Practical Access

Jatenzo is a branded prescription drug. Without insurance, 30-day supplies at standard doses range from roughly $400, $700. Many commercial insurance plans cover it with prior authorization demonstrating documented low testosterone and symptomatic hypogonadism per ICD-10 criteria. Medicare coverage requires careful documentation. [3]

Enclomiphene citrate prescribed off-label through a 503B compounding pharmacy typically costs $50, $150 per month, making it substantially more accessible out-of-pocket. Insurance rarely covers compounded medications. A 2022 analysis in the journal Urology Practice noted that cost is a leading driver of treatment discontinuation in men with hypogonadism, which affects real-world persistence data. [13]

Fertility Considerations in Detail

Fertility preservation separates these two drugs more than any other single variable. Any man who has not completed his family should be counseled explicitly before starting Jatenzo.

Sperm Banking Before Jatenzo

Sperm cryopreservation costs approximately $500, $1,000 for collection and $200, $500 annually for storage. That is a one-time decision that provides an indefinite backup. The American Society for Reproductive Medicine recommends sperm banking for any man starting testosterone therapy who may want biological children. [14] Given Jatenzo's reliable LH and FSH suppression, this recommendation applies directly.

Enclomiphene and Active Infertility Treatment

Men with oligozoospermia secondary to hypogonadotropic hypogonadism may see sperm concentration improve on enclomiphene. The 2016 Kim et al. Trial specifically enrolled men with concurrent hypogonadism and oligozoospermia, and the majority maintained sperm concentrations at or above the WHO 2021 reference value of 16 million/mL total count. [1] [15] That makes enclomiphene a reasonable bridge therapy while a couple pursues timed intercourse or IUI before moving to IVF.

Summary Comparison Table

| Feature | Enclomiphene Citrate | Jatenzo | |---|---|---| | FDA approval for hypogonadism | No | Yes (2019) | | Mechanism | SERM / axis stimulation | Exogenous testosterone | | Works in primary hypogonadism | No | Yes | | Preserves fertility | Yes | No | | Typical starting dose | 12.5 to 25 mg daily | 237 mg twice daily | | Blood pressure warning | No | Black box warning | | Erythrocytosis risk | Minimal | Present (5% above Hct 54%) | | LH/FSH effect | Raises both | Suppresses both | | Cost (out-of-pocket estimate) | $50, $150/month | $400, $700/month |